Trabectedin

Trabectedin is a tetrahydroisoquinoline alkaloid obtained from a Caribbean tunicate Ecteinascidia turbinata. Used for the treatment of soft tissue sarcoma and relapsed ovarian cancer. Among its listed roles, it functions as a antineoplastic agent, a marine metabolite, an anti-inflammatory agent, an angiogenesis modulating agent and an alkylating agent. It is an organic heteropolycyclic compound, an azaspiro compound, an oxaspiro compound, a bridged compound, a lactone, a polyphenol, an acetate ester, a hemiaminal, an organic sulfide, a tertiary amino compound and an isoquinoline alkaloid. It is grouped under the following drug class(es): Antineoplastic agents and Cytotoxics. Its therapeutic use is listed as anti-cancer agents and antineoplastics. The directory classifies it as a commercial API with a semi-synthetic source/manufacturing origin. Other names for this substance include Yondelis and Ecteinascidin. Its PubChem CID is 108150.

CAS No 114899-77-3
Molecular Formula C39H43N3O11S
Molecular Weight 761.8 g/mol
Synonyms [(1R,2R,3R,11S,12S,14R,26R)-5,6',12-trihydroxy-6,7'-dimethoxy-7,21,30-trimethyl-27-oxospiro[17,19,28-trioxa-24-thia-13,30-diazaheptacyclo[12.9.6.13,11.02,13.04,9.015,23.016,20]triaconta-4(9),5,7,15,20,22-hexaene-26,1'-3,4-dihydro-2H-isoquinoline]-22-yl] acetate

Frequently Asked Questions